How Severe Is Your Rheumatoid Arthritis?

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation, swelling, pain, stiffness, and, potentially, joint deformity. In autoimmune disease, the body's immune system mistakenly attacks healthy cells. While RA typically affects the joints, it can also affect the lungs, eyes, heart, and other parts of the body.

RA is a progressive disease, meaning that symptoms can worsen over time and can significantly affect long-term health and well-being. The disease affects everyone differently, so it can be hard for doctors to tell how severe a person's condition will become. However, certain factors may help predict the severity of your RA.

man with elbow pain

RealPeopleGroup / Getty Images

Number and Type of Affected Joints

The number and type of joints affected can help measure the level of severity in RA. Early-stage RA tends to affect just the smaller joints, such as in the hands and feet. However, as time goes by, more and larger joints like elbows, hips, and shoulders become affected as well.

The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) developed the ACR/EULAR classification criteria to confirm an RA diagnosis. The higher the number, the more severe your RA is likely to be. One of the criteria is joint involvement. An overall score of six out of 10 strongly indicates that you have RA, and higher numbers indicate more severe disease.

Serostatus

Serostatus refers to the state of having or not having detectable antibodies against a specific antigen, as measured by blood tests. In RA, tests look for the presence of what are called rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibodies.

Limitations of the tests include a low sensitivity, which means they could produce incorrect results. Being seropositive, meaning RF or CCP antibodies are detected in your body, usually indicates that RA symptoms are more severe.

CCP antibodies are highly specific, so it is very likely that you have RA if CCP antibodies are present.

Seropositive RA

Seropositive RA is when blood tests show that someone has RF or CCP antibodies, indicating that the person has a more severe case of RA. People with seropositive RA often have symptoms in other parts of their body besides their joints.

For example, nodules occur in 20%–30% of RA cases, almost exclusively in people with seropositive RA. These nodules are located most commonly near joints in the arms and elbows, but they also are prone to develop in the feet and knees. Rarely, nodules may form in the lungs, heart, or eyes.

People who have had active seropositive RA for many years may develop rheumatoid vasculitis. This is a condition in which blood vessels become inflamed.

Seronegative RA

Seronegative RA indicates a lack of CCP antibodies and RF in the blood. However, this does not necessarily mean you don't have RA.

One study has shown that study participants with seronegative RA had a better prognosis and less joint damage from the disease compared to individuals with seropositive RA. People with seronegative RA also demonstrated a better response to treatments, although the response was slower.

However, seronegative patients also ended up having similar progressive damage, as seen in X-rays, compared with seropositive patients. Therefore, seronegative status is not a harmless form of RA. Rather, it seems to show that seronegative patients have more active disease in the beginning.

Inflammatory Markers

Inflammatory markers like erythrocyte sedimentation rate and C-reactive protein indicate there is an inflammatory process in the body when they are elevated, like in the case of RA.

Erythrocyte Sedimentation Rate (ESR)

Erythrocyte sedimentation rate is a blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. Normally, red blood cells settle relatively slowly. A faster-than-normal rate may indicate inflammation in the body. ESR is one of the tests used to diagnose RA.

Whether the results of this test show how severe a person’s rheumatoid arthritis symptoms are is not known. Some individuals with known RA have tested normal for ESR levels.

C-Reactive Protein (CRP)

C-reactive protein is another test used to measure inflammation in the body. However, research on whether it's a reliable tool for RA assessment is mixed.

A study that tested CRP levels in a group of nearly 28,000 women not showing any signs of RA before the study found that CRP could not predict which women were at risk for developing RA. The same was true even when the test was performed closer to the time some women were actually diagnosed with RA..

Body fat can result in higher levels of CRP. So when CRP is used to measure inflammation in women with RA, the higher level of CRP could be due to body fat rather than disease activity.

Rheumatoid Arthritis Severity Scale (RASS)

The Rheumatoid Arthritis Severity Scale is designed to help doctors assess disease activity, functional impairment, and physical damage caused by RA.

Disease Activity Score (DAS)

The Disease Activity Score (DAS) measures disease activity, including swelling and tenderness, in 28 joints. DAS is based on a scale of one to 10, with one being the least severe and 10 being the most severe. This score helps your provider determine your baseline level of RA activity and track how it changes over time and throughout treatment.

One review performed by the ACR evaluated which measures accurately reflect RA disease activity. The Disease Activity Score with 28-joint counts (DAS-28) was among the final recommendations.

Functional Impairment

Joint inflammation and deformity associated with RA can lead to functional limitations. Functional limitations can cause problems with self-care tasks, such as grooming and dressing, as well as your ability to work, exercise, and socialize.

Physical Damage

Physical damage refers to symptoms such as joint deformity. It is one of the criteria used in evaluating RA severity. The more joint damage you have, the further along your RA is.

How Well Your Body Responds to RA Medications

Finding the appropriate medications or series of treatments to manage your RA is important to slowing its progression. By using a DAS score over the course of your treatment, your doctor will be able to track your response to medications.

Everyone is different, and you may not respond well to the initial treatments provided by your doctor. When this happens, it is easy to become discouraged. However, you can also view this as a process of getting closer to finding the right treatment for you.

Your Quality-of-Life Perception

Everyone has different physical, emotional, and psychological responses to their symptoms. Do not compare yourself to others or their progress with RA. Your body is unique, and it is the one you need to take care of.

In partnership with your healthcare provider, you can assess the severity of your RA, track its progress, and create a treatment plan that works for you. One study demonstrated that people with more severe RA pain tend to have a poorer perception of their social life, physical functioning, and overall health.

Rheumatoid Arthritis Doctor Discussion Guide

Doctor Discussion Guide Old Man

A Word From Verywell

RA disease severity can be managed by having a treatment plan in place and following it closely. Though the symptoms of RA can affect your quality of life, treatment can help slow the progression of the disease. Having a strong support network and staying on top of your illness can help ease the emotional strain that comes with living with a chronic condition.

Was this page helpful?
13 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. U.S. Centers for Disease Control and Prevention. Rheumatoid Arthritis (RA). Last reviewed July 27, 2020.

  2. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeArthritis Rheum. 2010;62(9):2569-81. doi:10.1002/art.27584

  3. Kumar B, Das MP, Misra AK. A cross-sectional study of association of serostatus and extra-articular manifestations in patients with rheumatoid arthritis in a teaching hospital. J Family Med Prim Care. 2020 June;9(6):2789-2793. doi:10.4103/jfmpc.jfmpc_99_20

  4. Johns Hopkins Arthritis Center. Rheumatoid arthritis signs and symptoms.

  5. Nordberg LB, Lillegraven S, Aga AB, Sexton J, Olsen IC, Lie E, Berner Hammer H, Uhlig T, van der Heijde D, Kvien TK, Haavardsholm EA. Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open. 2018 Nov 16;4(2):e000752. doi:10.1136/rmdopen-2018-000752

  6. MedlinePlus. Erythrocyte sedimentation rate (ESR). Updated July 31, 2020.

  7. Orr CK, Najm A, Young F, et al. The Utility and Limitations of CRP, ESR and DAS28-CRP in Appraising Disease Activity in Rheumatoid Arthritis. Front Med (Lausanne). 2018 Aug;5:185. doi:10.3389/fmed.2018.00185

  8. Orr CK, Najm A, Young F, et al. The Utility and Limitations of CRP, ESR and DAS28-CRP in Appraising Disease Activity in Rheumatoid Arthritis. Front Med (Lausanne). 2018 Aug;5:185. doi:10.3389/fmed.2018.00185

  9. Shadick NA, Cook NR, Karlson EW, et al. C-reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med. 2006;166(22):2490-2494. doi:10.1001/archinte.166.22.2490

  10. Giles JT, Bartlett SJ, Andersen R, Thompson R, Fontaine KR, Bathon JM. Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum. 2008;58(9):2632-2641. doi:10.1002/art.23766

  11. The American College of Rheumatology. Disease Activity Score (DAS).

  12. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practiceArthritis Care Res (Hoboken). 2012;64(5):640-647. doi:10.1002/acr.21649

  13. Martinec R, Pinjatela R, Balen D. QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS - A PRELIMINARY STUDYActa Clin Croat. 2019;58(1):157-166. doi:10.20471/acc.2019.58.01.20